Literature DB >> 26331818

Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.

Da-Wei Yang1,2, Yong Zhang1,2, Qun-Ying Hong1,2, Jie Hu1,2, Chun Li1,2, Bai-Shen Pan3, Qun Wang4, Fei-Hong Ding1, Jia-Xian Ou1, Fang-Lei Liu1, Dan Zhang1, Jie-Bai Zhou1, Yuan-Lin Song1,2, Chun-Xue Bai1,2,5.   

Abstract

BACKGROUND: This study applied a combined cancer biomarker panel to clinically identify small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) in a high-risk population.
METHODS: The serum levels of 4 biomarkers (progastrin-releasing peptide [ProGRP], carcinoembryonic antigen [CEA], squamous cell carcinoma antigen [SCC], and cytokeratin 19 fragment [CYFRA21-1]) were determined in 153 patients with a high risk of lung cancer (12 with a new diagnosis of SCLC, 52 with NSCLC, and 89 without lung cancer). Information about diagnosis delays was collected through interviews of all participants.
RESULTS: Significantly higher serum levels of ProGRP (P < .0001) were found among the SCLC patients versus the rest of the population. A receiver operating characteristic curve analysis established the cutoff values of ProGRP, CEA, SCC, and CYFRA21-1 as 300 pg/mL, 7.3 ng/mL, 3 ng/mL, and 6.5 ng/mL, respectively. The sensitivity and specificity of ProGRP in diagnosing SCLC were 75% and 100%, respectively. Among the 14 lung cancer patients with a false-negative computed tomography (CT) result, the diagnostic panel detected 8 additional cancers.
CONCLUSIONS: This panel increased the diagnostic specificity for high-risk subjects (those with renal failure being excluded), and auxiliary to a CT scan, it increased the sensitivity for patients with lung cancer. These results might be applied to shorten the diagnosis delay at health care institutions in China.
© 2015 American Cancer Society.

Entities:  

Keywords:  biomarker; delayed diagnosis; non-small cell lung cancer; progastrin-releasing peptide (ProGRP); small cell lung cancer

Mesh:

Substances:

Year:  2015        PMID: 26331818     DOI: 10.1002/cncr.29551

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

Review 2.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

Review 3.  Defining timeliness in care for patients with lung cancer: a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Muhammad Aziz Rahman
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

4.  Development and validation of a novel diagnostic model for assessing lung cancer metastasis in a Chinese population based on multicenter real-world data.

Authors:  Yiyong Yao; Cunling Yan; Wei Zhang; San-Gang Wu; Jie Guan; Gang Zeng; Qiang Du; Chun Huang; Hui Zhang; Huiling Wang; Yanfeng Hou; Zhiyan Li; Lixin Wang; Yijie Zheng; Xun Li
Journal:  Cancer Manag Res       Date:  2019-10-29       Impact factor: 3.989

5.  Prognostic model based on circular RNA circPDK1 for resected lung squamous cell carcinoma.

Authors:  Xiao Sun; Maolong Wang; Rongjian Xu; Dongyang Zhang; Ao Liu; Yuanyong Wang; Tong Lu; Yanlu Xin; Yandong Zhao; Yunpeng Xuan; Tong Qiu; Hao Wang; Shicheng Li; Yang Wo; Dahai Liu; Jinpeng Zhao; Bo Fu; Yaliang Lan; Yudong Han; Wenjie Jiao
Journal:  Transl Lung Cancer Res       Date:  2019-12

6.  The usefulness of CYFRA 21-1 to diagnose and predict preeclampsia: a nested case-control study.

Authors:  Lorenz Kuessel; Harald Zeisler; Robin Ristl; Julia Binder; Petra Pateisky; Maximilian Schmid; Julian Marschalek; Thomas Perkmann; Helmuth Haslacher; Heinrich Husslein
Journal:  BMC Pregnancy Childbirth       Date:  2016-11-03       Impact factor: 3.007

7.  Instability of Plasma and Serum Progastrin-Releasing Peptide During Repeated Freezing and Thawing.

Authors:  Jae-Eun Lee; Jin-Hyun Lee; Maria Hong; Seul-Ki Park; Ji-In Yu; So-Youn Shin; Shine Young Kim
Journal:  Osong Public Health Res Perspect       Date:  2016-11-16

8.  Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units.

Authors:  Sonia Blanco-Prieto; Loretta De Chiara; Mar Rodríguez-Girondo; Lorena Vázquez-Iglesias; Francisco Javier Rodríguez-Berrocal; Alberto Fernández-Villar; María Isabel Botana-Rial; María Páez de la Cadena
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

9.  Elevated Squamous Cell Carcinoma Antigen, Cytokeratin 19 Fragment, and Carcinoembryonic Antigen Levels in Diabetic Nephropathy.

Authors:  Jianzhong Chen; Feng Tao; Bin Zhang; Qingguang Chen; Yan Qiu; Qian Luo; Yanna Gen; Jiali Meng; Jue Zhang; Hao Lu
Journal:  Int J Endocrinol       Date:  2017-07-04       Impact factor: 3.257

10.  Diagnostic and prognostic values of cerebrospinal fluid CYFRA 21-1 in patients with leptomeningeal carcinomatosis.

Authors:  Jae-Won Hyun; Ji Hyun Park; Boo Gil Kang; Eun Young Park; Boram Park; Jungnam Joo; Jong Kuk Kim; Su-Hyun Kim; Jee Hyang Jeong; Hyang Woon Lee; Kee Duk Park; Kyung Gyu Choi; Sang-Hyun Hwang; Ho-Shin Gwak; Ho Jin Kim
Journal:  Oncotarget       Date:  2017-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.